$INTA(0192.MY)$
INTA's valuation has been in single-digit PE for a long time, and its turnover and profit all broke through record highs in 2023. Stock prices had no momentum before because they hadn't obtained contracts for a while, so they couldn't attract investors.
As the saying goes: 3 years without opening, 3 years after opening. INTA obtained a total of 3 construction contracts with a total value of RM743 mils in April. The Order Book reached a record high, and the stock price once broke through the RM0.40 mark.
Assuming continued growth in 2024 and 2025, good returns are expected in the future. INTA is a bit like KSL in industrial stocks. The valuation is very low, and it is in a situation where the valuation is being revalued.

After reaching a historic closing high in its stock price in December last year, $Apple(AAPL.US)$ has seen a nearly 12% decline this year, erasing over $300 billion in market capitalization.
Some analysts with a pessimistic view believe that the stock, which did not maintain the support level of $180 last week and dipped below $170 during different times on Tuesday, might indicate a potential retracement to its October low of $1...

In February, NVIDIA's explosive earnings sparked a global stock market rally, with the $S&P 500 Index(.SPX.US)$ and $Dow Jones Industrial Average(.DJI.US)$ indices hitting new highs and the Nasdaq approaching a historic peak. Now, the U.S. stock market is poised for a series of significant events in March:
March 5, 2024, will mark "Super Tuesday" in the U.S. presidential election, the day of the primary elections. On this day, ...

The pharma giant $Eli Lilly and Co(LLY.US)$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...